These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25995341)

  • 1. Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
    Groß C; Steiger K; Sayyed S; Heid I; Feuchtinger A; Walch A; Heß J; Unger K; Zitzelsberger H; Settles M; Schlitter AM; Dworniczak J; Altomonte J; Ebert O; Schwaiger M; Rummeny E; Steingötter A; Esposito I; Braren R
    Clin Cancer Res; 2015 Oct; 21(19):4440-50. PubMed ID: 25995341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next Generation of Preclinical Liver Cancer Models.
    Weber A; O'Connor T; Heikenwalder M
    Clin Cancer Res; 2015 Oct; 21(19):4254-6. PubMed ID: 26169964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
    Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
    Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
    Shi JH; Liu SZ; Wierød L; Scholz H; Anmarkrud JA; Huitfeldt HS; Zhang SJ; Line PD
    J Surg Oncol; 2013 Mar; 107(4):393-401. PubMed ID: 22927239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
    Kuczynski EA; Kerbel RS
    Chin J Cancer; 2016 Nov; 35(1):97. PubMed ID: 27887628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma.
    Zhao YL; Guo QQ; Yang GR; Wang QD
    J Zhejiang Univ Sci B; 2014 Aug; 15(8):713-9. PubMed ID: 25091989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
    Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL
    J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
    Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
    Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
    Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
    Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
    Ou DL; Chang CJ; Jeng YM; Lin YJ; Lin ZZ; Gandhi AK; Liao SC; Huang ZM; Hsu C; Cheng AL
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2021-31. PubMed ID: 25160036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.
    Yang SH; Lin J; Lu F; Han ZH; Fu CX; Lv P; Liu H; Gao DM
    J Magn Reson Imaging; 2017 Jan; 45(1):270-280. PubMed ID: 27299302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
    Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
    Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP; Ho RL; Chen GG; Lai PB
    Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
    Kapanadze T; Gamrekelashvili J; Ma C; Chan C; Zhao F; Hewitt S; Zender L; Kapoor V; Felsher DW; Manns MP; Korangy F; Greten TF
    J Hepatol; 2013 Nov; 59(5):1007-13. PubMed ID: 23796475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
    Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
    Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
    Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
    [No Abstract]   [Full Text] [Related]  

  • 19. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ohata Y; Shimada S; Akiyama Y; Mogushi K; Nakao K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M; Tanaka S
    Mol Cancer Ther; 2017 Jun; 16(6):1155-1165. PubMed ID: 28246302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
    Zahavi T; Lanton T; Divon MS; Salmon A; Peretz T; Galun E; Axelrod JH; Sonnenblick A
    Oncotarget; 2016 Jan; 7(4):4860-70. PubMed ID: 26695439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.